SCHEMBL24596245

SCHEMBL24596245

CCOC(=O)c1ncoc1-c1ccc(C(F)(F)F)nc1Nc1cccc(F)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIRT5 Q9NXA8 1/20 0.39
SYK P43405 3/20 0.38
LMNA P02545 2/20 0.35
THRB P10828 1/20 0.35
TGFBR1 P36897 1/20 0.34
PDE4B Q07343 3/20 0.34
PDE11A Q9HCR9 3/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 1/20 0.33
CACNA1B Q00975 1/20 0.33
APBA1 Q02410 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CDK2 P24941 1/20 0.33
GSK3B P49841 1/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29790079 1.00 SIRT5 (0.39) SIRT5SYKLMNATHRBTGFBR1
SCHEMBL24596387 0.89 MAPT (0.41) SIRT5SYKLMNAPDE4BPDE11A
SCHEMBL29789936 0.89 MAPT (0.41) SIRT5SYKLMNAPDE4BPDE11A
SCHEMBL24596361 0.85 TGFBR1 (0.41) SYKTGFBR1ALDH1A1CACNA1BAPBA1
SCHEMBL26631694 0.85 BRD4 (0.41) SYKTGFBR1NPC1RAB9AALDH1A1
SCHEMBL29790062 0.85 TGFBR1 (0.41) SYKTGFBR1ALDH1A1CACNA1BAPBA1
SCHEMBL24596365 0.81 BRD4 (0.37) SYKTGFBR1NPC1RAB9ASMN1; SMN2
SCHEMBL29790055 0.81 BRD4 (0.37) SYKTGFBR1NPC1RAB9ASMN1; SMN2
SCHEMBL26631721 0.77 SYK (0.37) SYKLMNANPC1SMN1; SMN2ALDH1A1
SCHEMBL24596338 0.75 MAPT (0.41) SIRT5SYKLMNATGFBR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A SIRT5 4094/4885SYK 4805/4885LMNA 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.